Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
| Revenue (TTM) | $959.90M |
| Gross Profit (TTM) | $723.99M |
| EBITDA | $255.99M |
| Operating Margin | 34.20% |
| Return on Equity | 20.50% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $16.63 |
| Book Value | $17.19 |
| Price-to-Book | 2.36 |
| Price-to-Sales (TTM) | 2.30 |
| EV/Revenue | 1.921 |
| EV/EBITDA | 6.59 |
| Quarterly Earnings Growth (YoY) | 88.20% |
| Quarterly Revenue Growth (YoY) | 30.30% |
| Shares Outstanding | $58.24M |
| Float | $52.09M |
| % Insiders | 1.22% |
| % Institutions | 99.67% |
Volatility is currently expanding
Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
This, despite the move being expected. The company's new CEO will take up the post at the beginning of next year.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HRMY and any ticker you trade — then tracks every position and per-strategy win rate.
